Cartesian Therapeutics, Inc. (RNAC)
NASDAQ: RNAC · Real-Time Price · USD
16.03
-0.51 (-3.08%)
Sep 20, 2024, 4:00 PM EDT - Market closed
Company Description
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases.
It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases.
The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases.
Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.
Cartesian Therapeutics, Inc.
| Country | United States |
| Founded | 2007 |
| IPO Date | Jun 22, 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 38 |
| CEO | Carsten Brunn |
Contact Details
Address: 704 Quince Orchard Road Gaithersburg, Maryland 20878 United States | |
| Phone | 617 923 1400 |
| Website | cartesiantherapeutics.com |
Stock Details
| Ticker Symbol | RNAC |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001453687 |
| CUSIP Number | 816212104 |
| ISIN Number | US8162123025 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Carsten Brunn Ph.D. | President, Chief Executive Officer and Director |
| Blaine T. Davis | Chief Financial Officer |
| Dr. Metin Kurtoglu M.D., Ph.D. | Chief Technology Officer |
| Dr. Chris Jewell Ph.D. | Chief Scientific Officer |
| Matthew Bartholomae J.D. | General Counsel and Secretary |
| Dr. Milos Miljkovic M.D., Ph.D. | Chief Medical Officer |
| Dr. Emily English Ph.D. | SVice President and Head of Manufacturing |
| Yi Zhang Ph.D. | Senior Director of Technology |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 9, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Aug 16, 2024 | DEF 14A | Other definitive proxy statements |
| Aug 12, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Aug 8, 2024 | 10-Q | Quarterly Report |
| Aug 8, 2024 | 8-K | Current Report |
| Aug 2, 2024 | PRE 14A | Other preliminary proxy statements |
| Aug 2, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Jul 17, 2024 | D | Notice of Exempt Offering of Securities |
| Jul 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jul 5, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |